RE: Avacta Group plc Research Note - 18.06.202018 Jun 2020 13:41
Thanks for that Rorkes, it's a very positive article for Avacta due to the following extract -
"A possible future antibody-based treatment could potentially be used as a preventative approach for COVID-19 and could be complementary to vaccines, e.g. for people who may not be able to have a vaccination or to provide added protection for high-risk populations. In addition, we plan to evaluate our monoclonal antibody combination candidate as a potential treatment for patients with COVID-19. "
So, even AZ agree that treatments will be needed in addition to the vaccine they are developing. There's a lot of room in this market!